Enhancement of cytotoxic effect of anticancer agents on renal cell carcinoma

Japanese Journal of Urology

Volumn 87, Issue 8, 1996, Pages 1041-1047

  Okano, Manabu ^a   Kawamoto, Syogo ^a   Nezasa, Shinichi ^a   Tamaki, Masayoshi ^a   Ehara, Hidetoshi ^a   Yamada, Shinichirou ^a   Deguchi, Takashi ^a   Kawada, Yukimichi ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

cyclosporin A; renal cell carcinoma; verapamil

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; VERAPAMIL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER STAGING; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; REVIEW;

EID: 0029786042     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.87.1041     Document Type: Review

References (21)

1. Kanamaru, H., Kakehi, Y., Yoshida, O., Nakanishi, S., Pastan, I. and Gottesman, M.M.: MDR1 RNA levels in human renal carcinomas: Correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J. Natl. Cancer Inst., 81, 844-849, 1989.
2. Mickisch, G.H., Roehrich, K., Koessig, J., Foster, S., Tschada, R.K. and Alken, P.M.: Mechanism and modulation of multidrug resistance in primary human renal cell carcinoma. J. Urol., 144, 755-759, 1990.
3. Nicardipine Vinca Alkaloid preliminary report, 10, 2330-2334, 1984.
4. Vindesine sulfate, Cis-diammine dichloroplatinum (II) 2 11, 943-947, 1984.
5. Benson, A.B. III, Trump, D.L., Koeller, J.M., Egorin, M.I., Olman, E.A., Witte, R.S., Davis, T. E. and Tormey, D.C.: Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat. Rep., 69, 795-799, 1985.
6. Ozols, R.F., Cunnion, R.E., Klecker, R.W. Jr., Hamilton, T.C., Ostchega, Y., Parrillo, J.E. and Young, R.C.: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol., 5, 641-647, 1987.
7. Nishiyama, K., Shirahama, T., Yoshimura, A., Sumizawa, T., Furukawa, T., Ichikawa-Haraguchi, M., Akiyama, S. and Ohi, Y.: Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer, 71, 3611-3619, 1993.
8. Quesada, T.R., Swanson, D.A., Trindada, A. and Guttermann, J.U.: Renal cell carcinoma: Antitumor effect of leukocyte interferon. Cancer Res., 43, 940-947, 1983.
9. [abstract]. Proc. Jpn. Cancer Assoc., 53, 662, 1994.
10. (MDR1) mRNA J. Jpn. Soc. Cancer Ther., 28, 345, 1993.
11. Leyland-Jones, B., Dalton, W., Fisher, G.A. and Sikic, B.I.: Reversal of multidrug resistance to cancer chemotherapy. Cancer, 72, 3484-3488, 1993.
12. ATPassay 17, 2235-2239, 1990.
13. Cardarelli, C.O., Aksentijevich, I., Pastan, I and Gottesman, M.M.: Differential effect of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res., 55, 1086-1091, 1995.
14. Keilhauer, C., Emling, F., Raschak, M., Gries, J and Schlick, E.: The use of R-verapamil (R-VPM) is superior to racemic VPM in breaking multidrug resistance (MDR) of malignant cells [abstract]. Proc. Am. Assoc. Cancer Res., 30, 503, 1989.
15. Keller, R.P., Altermatt, H.J., Nooter, K., Poschmann, G., Laissue, J A., Bollinger, P. and Hiestand, P.C.: SDZ PSC 833, a nonimmunosupessive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50, 593-597, 1992.
16. Boesch, D., Gaveraux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P. and Loor, F.: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res, 51, 4226-4233, 1991.
17. Dalton, W.S., Grogan, T.M., Meltzer, P.S., Scheper, R J., Durie, B.G.M., Taylor, C.W., Miller, T. P and Salmon, S.E.: Drug resistance in multiple myeloma and non-Hodgikin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemothrapy. J. Clin. Oncol., 7, 415-424, 1989.